Carcinogenic Alkylating Agents

Sharma, Vyom; Upton, Patricia B.; Swenberg, James A.; La, David K.

doi:10.1016/b978-0-12-801238-3.95690-3

Cited by 3 publications

(2 citation statements)

References 182 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This process is known as alkylation, and it can lead to genetic changes and potential cancer development. 52…”

Section: Transcriptomic Approaches To Predict Environmental Hepatocar...mentioning

confidence: 99%

Toxicogenomics Approaches to Address Toxicity and Carcinogenicity in the Liver

Pandiri,

Auerbach,

Stevens

et al. 2023

Toxicol Pathol

View full text Add to dashboard Cite

Toxicogenomic technologies query the genome, transcriptome, proteome, and the epigenome in a variety of toxicological conditions. Due to practical considerations related to the dynamic range of the assays, sensitivity, cost, and technological limitations, transcriptomic approaches are predominantly used in toxicogenomics. Toxicogenomics is being used to understand the mechanisms of toxicity and carcinogenicity, evaluate the translational relevance of toxicological responses from in vivo and in vitro models, and identify predictive biomarkers of disease and exposure. In this session, a brief overview of various transcriptomic technologies and practical considerations related to experimental design was provided. The advantages of gene network analyses to define mechanisms were also discussed. An assessment of the utility of toxicogenomic technologies in the environmental and pharmaceutical space showed that these technologies are being increasingly used to gain mechanistic insights and determining the translational relevance of adverse findings. Within the environmental toxicology area, there is a broader regulatory consideration of benchmark doses derived from toxicogenomics data. In contrast, these approaches are mainly used for internal decision-making in pharmaceutical development. Finally, the development and application of toxicogenomic signatures for prediction of apical endpoints of regulatory concern continues to be area of intense research.

show abstract

“…This process is known as alkylation, and it can lead to genetic changes and potential cancer development. 52…”

Section: Transcriptomic Approaches To Predict Environmental Hepatocar...mentioning

confidence: 99%

Toxicogenomics Approaches to Address Toxicity and Carcinogenicity in the Liver

Pandiri,

Auerbach,

Stevens

et al. 2023

Toxicol Pathol

View full text Add to dashboard Cite

show abstract

“…Nitrogen mustards are a class of alkylating agents that forms N-alkylaziridinium ions [58]. They induce DNA adducts formation, exert anti-replicative effects and apoptosis [63,64]. Examples of compounds under this class include Cyclophosphamide, Ifosfamide, Melphalan, Mechlorethamine, Chlorambucil, Estramustine and Bendamustine.…”

Section: Alkylating Agentsmentioning

confidence: 99%

Current Trends in the Treatment of Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Senthilnathan

2020

J. Pharm. Nutr. Sci.

View full text Add to dashboard Cite

Breast cancer affect almost 1 in 8 women and it is highest in developed and developing countries. There are many drugs exist for the treatment of breast cancer, but still the incidence of mortality and morbidity are high among all cancer types in most countries. Even though the conventional therapies play a major role in the management of breast cancer, its complications are obvious and unavoidable. The newer targeted drug therapy came in place to reduce complications in some extent, but not fully. Hence, a review was aimed to analyse the efficacy and safety of newer anticancer drugs that approved for the treatment of breast cancer by US-FDA from 2017 to 2019. The Olaparib, Talazoparib, and Ribociclib are the newly approved drugs for the treatment of breast cancer during this review period. Among these new drugs, Olaparib and Talazoparib alone or in combination with other anticancer drugs considered as safe and efficacious. Patients with Olaparib or Talazoparib as monotherapy have median progression-free survival of 2.8 to 8.6 months longer and has 42-46% lower risk of death (P

show abstract